Medtronic Secures FDA Clearance for Nellcor™ Pulse Oximetry System, Enhancing Reliability Across Diverse Patients
MDT is trading near its 52-week low of $73.31 (9.8% above the low) on light trading volume (0.3× avg).
Summary
Medtronic received FDA 510(k) clearance for its Nellcor™ pulse oximetry system with Nell-EQ™ intelligent processor. This new technology is designed to improve the reliability of oxygen saturation and pulse rate monitoring across diverse patient populations and skin tones, addressing a known industry challenge. This clearance follows earlier positive study results and a Safer Technologies Program (STeP) designation, further strengthening Medtronic's competitive position in a critical medical device category. The system is expected to be available globally in the coming months.
At the time of this announcement, MDT was trading at $80.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $103.3B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.